These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28340373)

  • 1. Influence of sex on cardiovascular drug responses: role of estrogen.
    Abdel-Rahman AA
    Curr Opin Pharmacol; 2017 Apr; 33():1-5. PubMed ID: 28340373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex hormones in the cardiovascular system.
    dos Santos RL; da Silva FB; Ribeiro RF; Stefanon I
    Horm Mol Biol Clin Investig; 2014 May; 18(2):89-103. PubMed ID: 25390005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Future of Cardiovascular Therapeutics.
    MacRae CA; Roden DM; Loscalzo J
    Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sex differences and cardiovascular drugs].
    Løchen ML; Kvan E
    Tidsskr Nor Laegeforen; 2010 Feb; 130(4):382-4. PubMed ID: 20220863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender and the endothelium.
    Kublickiene K; Luksha L
    Pharmacol Rep; 2008; 60(1):49-60. PubMed ID: 18276985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abstracts of the 11th International Congress on Cardiovascular Pharmacotherapy. Montreal, Canada, 18-21 May 2002.
    Cardiovasc Drugs Ther; 2002; 16 Suppl 1():5-116. PubMed ID: 12108434
    [No Abstract]   [Full Text] [Related]  

  • 7. The importance of drug discovery for treatment of cardiovascular diseases.
    Kennedy C
    Future Med Chem; 2013 Mar; 5(4):355-7. PubMed ID: 23495678
    [No Abstract]   [Full Text] [Related]  

  • 8. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC.
    Rosano GM; Lewis B; Agewall S; Wassmann S; Vitale C; Schmidt H; Drexel H; Patak A; Torp-Pedersen C; Kjeldsen KP; Tamargo J
    Eur Heart J; 2015 Oct; 36(40):2677-80. PubMed ID: 25948737
    [No Abstract]   [Full Text] [Related]  

  • 9. Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach.
    Bisi A; Gobbi S; Belluti F; Rampa A
    Curr Med Chem; 2013; 20(13):1759-82. PubMed ID: 23410171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of vascular mechanisms: bridging the gap between basic research and clinical trials.
    Collier J; Vallance P
    Trends Pharmacol Sci; 1993 Jul; 14(7):257-8. PubMed ID: 8212320
    [No Abstract]   [Full Text] [Related]  

  • 11. Abstracts of the 13th International Congress on Cardiovascular Pharmacotherapy. November 29-December 2, 2007. Antalya, Turkey.
    Remme WJ
    Cardiovasc Drugs Ther; 2007 Nov; 21 Suppl 1(1):S6-43. PubMed ID: 17963033
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular receptors as drug targets. Eur omega Conferences' Cardiovascular receptors as drug targets. Institut Pasteur, Paris, France, 3-4 October 1996.
    Maack T
    Mol Med Today; 1997 Mar; 3(3):101-2. PubMed ID: 9095483
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.
    Chow BS; Allen TJ
    Clin Sci (Lond); 2016 Aug; 130(15):1307-26. PubMed ID: 27358027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of pharmacotherapy of osteoporosis in cardiology patients.
    Zapolski T; Wysokiński A
    Cardiol J; 2010; 17(4):335-43. PubMed ID: 20690088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic implications of the gender-specific aspects of cardiovascular disease.
    Regitz-Zagrosek V
    Nat Rev Drug Discov; 2006 May; 5(5):425-38. PubMed ID: 16672926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epicardial fat: a new cardiovascular therapeutic target.
    Iacobellis G
    Curr Opin Pharmacol; 2016 Apr; 27():13-8. PubMed ID: 26848943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Flavonoids.
    Sánchez M; Romero M; Gómez-Guzmán M; Tamargo J; Pérez-Vizcaino F; Duarte J
    Curr Med Chem; 2019; 26(39):6991-7034. PubMed ID: 30569843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models.
    Arnal JF; Valéra MC; Payrastre B; Lenfant F; Gourdy P
    Thromb Res; 2012 Oct; 130 Suppl 1():S7-11. PubMed ID: 23026669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of sphingosine-1-phosphate (S1P).
    Levkau B
    Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.